This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Home hemodialysis | |
---|---|
Specialty | Nephrologist |
Home hemodialysis (HHD) is the provision of hemodialysis to purify the blood of a person whose kidneys are not working normally, in their own home. One advantage to doing dialysis at home is that it can be done more frequently and slowly, which reduces the "washed out" feeling and other symptoms caused by rapid ultrafiltration, and it can often be done at night, while the person is sleeping.
People on home hemodialysis are followed by a nephrologist who writes the dialysis prescription and they rely on the support of a dialysis unit for back-up treatments and case management. Studies show that HHD improves patients' sense of well-being; the more they know about and control their own treatment the better they are likely to do on dialysis. [1]
HHD was introduced in the 1960s as a way to conserve scarce healthcare resources. [2]
There are three basic schedules of HHD and these are differentiated by the length and frequency of dialysis and the time of day the dialysis is carried out. They are as follows:
Thus an NHHD schedule results in a larger dose of hemodialysis per week, as do some SDHHD. More total time dialyzing, shorter periods between treatments and the fact that fluid removal speeds can be lower (thus reducing the symptoms resulting from rapid ultrafiltration), accounts for the advantages of these schedules over conventional ones.
A frequent NHHD schedule has been shown to have better clinical outcomes than a conventional schedule and evidence is mounting that clinical outcomes are improved with each increase in treatment frequency. [3] [4]
Home hemodialysis started in the early 1960s. Who started it is in dispute. Groups in Boston, London, Seattle [27] and Hokkaidō all have a claim.
The Hokkaidō group was slightly ahead of the others, with Nosé's publication of his PhD thesis (in 1962), which described treating patients outside of the hospital for acute kidney injury due to drug overdoses. In 1963, he attempted to publish these cases in the ASAIO Journal but was unsuccessful, which was later described in the ASAIO Journal when people were invited to write about unconventional/crazy rejected papers. [28] That these treatments took place in people's homes is hotly disputed by Shaldon [29] and he has accused Nosé of a faulty memory and not being completely honest, as allegedly revealed by some shared Polish Vodka, many years earlier.
The Seattle group (originally the Seattle Artificial Kidney Center, later the Northwest Kidney Centers) started their home program in July 1964. It was inspired by the fifteen-year-old daughter of a collaborator's friend, who went into kidney failure due to lupus erythematosus, and had been denied access to dialysis by their patient selection committee. Dialysis treatment at home was the only alternative and managed to extend her life another four years. Dr. Chris Blagg has stated that the first training predated the establishment of the home program: the "first home patient wasn't part of our program at all, he was president of a big Indian corporation, lived in Madras, and he came to Seattle just before I came in '63. He came in early '63, again, with his doctor and his wife and Dr. Scribner trained them to do dialysis at home and they went home to Madras." [30] [31]
In September 1964 the London group (led by Shaldon) started dialysis treatment at home. In the late 1960s, Shaldon introduced HHD in Germany. [32]
Home hemodialysis machines have changed considerably since the inception of the practice. Nosé's machine consisted of a coil (to transport the blood) placed in a household (electric) washing machine filled with dialysate. It did not have a pump and blood transport through the coil was dependent on the patient's heart. The dialysate was circulated by turning on the washing machine (which mixed the dialysate and resulted in some convection) and Nosé's experiments show that this indeed improved the clearance of toxins.
In the USA there has been a large decline in home hemodialysis over the past 30 years. In the early 1970s, approximately 40% of patients used it. Today, it is used by approximately 0.4%. [27] In other countries NHHD use is much higher. In Australia approximately 11% of ESRD patients use NHHD. [27]
The large decline in HHD seen in the 1970s and early 1980s is due to several factors. It coincides with the introduction and arise of continuous ambulatory peritoneal dialysis (CAPD) in the late 1970s, an increase in the age and the number of comorbidities (degree of "sickness") in the ESRD population, and, in some countries such USA, changes in how dialysis care is funded (which lead to more hospital-based hemodialysis).
Home night-time (nocturnal) hemodialysis was first introduced by Baillod et al. [33] in the UK and grew popular in some centers, such as the Northwest Kidney Centers, but then declined in the 1970s (coinciding with the decline in HHD). Since the early 1990s, NHHD has become more popular again. Uldall [34] and Pierratos [35] [36] started a program in Toronto, which advocated long night-time treatments (and coined the term 'nocturnal home hemodialysis') and Agar [10] in Geelong converted his HHD patients to NHHD.
Currently, three hemodialysis machines are used for home hemodialysis in the United States. They are made by B. Braun Melsungen, Fresenius and NxStage, a division of Fresenius Medical Care. The systems take different approaches to the process of dialysis. The B Braun is a standard hemodialysis machine and is used in-center and at home. The Fresenius "Baby K" home machine is close to a standard hemodialysis machine, but somewhat more user friendly and smaller. Both the B Braun and the Fresenius Baby K require a separate reverse osmosis water treatment system which allow dialysate flow rates generally from 300 to 800 ml/minute.
The NxStage System One cycler uses far less dialysate per treatment with a maximum dialysate flow rate of 200 ml/minute but generally runs at rates less than 150 ml/minute. The NxStage System One can be used with bags of ultrapure dialysate – from 15 to 60 liters per treatment (see photo showing treatment in process). This allows the System One to be transportable; as of 2008 the company supports travel within the continental US and will assist travel to Alaska and Hawaii (travel to AK & HI will result in the patient having additional out of pocket costs). Generally, the supplies including the dialysate are delivered as they are scheduled to be used, either bimonthly or monthly but the amount of supplies can become a concern. The System One can also use a separate dialysate production device manufactured by NxStage – the PureFlow. The PureFlow uses a deionization process to create a 60, 50 or 40 liter batch of dialysate depending on the SAK (bag of dialysate concentrate) specified by the MD. A batch has a 96-hour shelf life and is usually used for two or three treatments, although some patients are using the entire 60, 50 or 40 liter batch for a single extended treatment.
Patients on frequent daytime hemodialysis have done well on short sessions (1.5 hours) given 6 times per week, although this would total 9 hours per week, and is fewer hours per week than most patients being dialyzed 3x/week. When changing from a 3x/week to a 6x/week schedule, if total weekly time is left the same (each session length cut in half), patients typically will still remove a little bit more waste products initially than with conventional schedules, since the blood levels of toxins during the initial hour of dialysis are higher than in subsequent hours. Most patients treating themselves "daily" (6x/week) with daytime hemodialysis use session lengths of 2–3 hours. Longer session lengths give more benefit in terms of fluid and especially, phosphate removal. However, unless sessions are prolonged beyond 3–4 hours, almost all 6x/week patients will still require phosphate binders. Fluid and phosphate removal with "daily" dialysis are made more difficult because patients often feel better and increase protein (and thus also, phosphate) as well as fluid intake.
When nocturnal dialysis is given 3 or 3.5 times (every other night) per week, the total weekly duration of dialysis is markedly prolonged, since each session typically lasts 6–8 hours, compared to 3–4 hours for conventional dialysis. This gives benefits in terms of fluid removal and phosphate removal, although about 1/2 to 2/3 of patients receiving this kind of treatment will still require phosphate binders. When such long nocturnal sessions are given 6x/week, in almost all patients phosphate binders can be stopped, and in a substantial number, phosphate needs to be added to the dialysate to prevent phosphate depletion. Because of the long weekly dialysis time, fluid removal is very well controlled, as the rate of ultrafiltration is quite low.
Whereas adequacy of conventional dialysis is measured by urea reduction ratio URR or Kt/V, the question of adequacy of more frequent dialysis is based on opinion only and not on controlled trials. The KDOQI 2006 adequacy group, in their Clinical Practice Recommendations, suggested using the Standardized Kt/V as a minimum standard of adequacy for dialysis schedules other than 3x/week. A minimum standardized Kt/V value of 2.0 per week was suggested.
Kidney dialysis is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally. Along with kidney transplantation, it is a type of renal replacement therapy.
Kidney failure, also known as end-stage renal disease (ESRD), is a medical condition in which the kidneys can no longer adequately filter waste products from the blood, functioning at less than 15% of normal levels. Kidney failure is classified as either acute kidney failure, which develops rapidly and may resolve; and chronic kidney failure, which develops slowly and can often be irreversible. Symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications of acute and chronic failure include uremia, hyperkalemia, and volume overload. Complications of chronic failure also include heart disease, high blood pressure, and anaemia.
Uremia is the term for high levels of urea in the blood. Urea is one of the primary components of urine. It can be defined as an excess in the blood of amino acid and protein metabolism end products, such as urea and creatinine, which would be normally excreted in the urine. Uremic syndrome can be defined as the terminal clinical manifestation of kidney failure. It is the signs, symptoms and results from laboratory tests which result from inadequate excretory, regulatory, and endocrine function of the kidneys. Both uremia and uremic syndrome have been used interchangeably to denote a very high plasma urea concentration that is the result of renal failure. The former denotation will be used for the rest of the article.
Hemodialysis, also spelled haemodialysis, or simply dialysis, is a process of filtering the blood of a person whose kidneys are not working normally. This type of dialysis achieves the extracorporeal removal of waste products such as creatinine and urea and free water from the blood when the kidneys are in a state of kidney failure. Hemodialysis is one of three renal replacement therapies. An alternative method for extracorporeal separation of blood components such as plasma or cells is apheresis.
Chronic kidney disease (CKD) is a type of long-term kidney disease, in which either there is a gradual loss of kidney function occurs over a period of months to years, or abnormal kidney structure. Initially generally no symptoms are seen, but later symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications can relate to hormonal dysfunction of the kidneys and include high blood pressure, bone disease, and anemia. Additionally CKD patients have markedly increased cardiovascular complications with increased risks of death and hospitalization. CKD can lead to kidney failure requiring kidney dialysis or kidney transplantation.
Peritoneal dialysis (PD) is a type of dialysis that uses the peritoneum in a person's abdomen as the membrane through which fluid and dissolved substances are exchanged with the blood. It is used to remove excess fluid, correct electrolyte problems, and remove toxins in those with kidney failure. Peritoneal dialysis has better outcomes than hemodialysis during the first couple of years. Other benefits include greater flexibility and better tolerability in those with significant heart disease.
In medicine, Kt/V is a number used to quantify hemodialysis and peritoneal dialysis treatment adequacy.
Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). The term "renal osteodystrophy" was coined in 1943, 60 years after an association was identified between bone disease and kidney failure.
Artificial kidney is often a synonym for hemodialyzer, but may also refer to the other renal replacement therapies that are in use and/or in development. This article deals mainly with bio-artificial kidneys featuring cells that are grown from renal cell lines/renal tissue.
Hemofiltration, also haemofiltration, is a renal replacement therapy which is used in the intensive care setting. It is usually used to treat acute kidney injury (AKI), but may be of benefit in multiple organ dysfunction syndrome or sepsis. During hemofiltration, a patient's blood is passed through a set of tubing via a machine to a semipermeable membrane where waste products and water are removed by convection. Replacement fluid is added and the blood is returned to the patient.
Standardized Kt/V, also std Kt/V, is a way of measuring (renal) dialysis adequacy. It was developed by Frank Gotch and is used in the United States to measure dialysis. Despite the name, it is quite different from Kt/V. In theory, both peritoneal dialysis and hemodialysis can be quantified with std Kt/V.
Renal replacement therapy (RRT) is therapy that replaces the normal blood-filtering function of the kidneys. It is used when the kidneys are not working well, which is called kidney failure and includes acute kidney injury and chronic kidney disease. Renal replacement therapy includes dialysis, hemofiltration, and hemodiafiltration, which are various ways of filtration of blood with or without machines. Renal replacement therapy also includes kidney transplantation, which is the ultimate form of replacement in that the old kidney is replaced by a donor kidney.
In medicine, nocturnal dialysis, refers to (renal) dialysis done at night. It usually is a reference to nocturnal hemodialysis, but could also refer to peritoneal dialysis which is typically done at night.
Dialysis disequilibrium syndrome (DDS) is the collection of neurological signs and symptoms, attributed to cerebral edema, during or following shortly after intermittent hemodialysis or CRRT.
Robert Provenzano is an American nephrologist. He is also an Associate Clinical Professor of Medicine at Wayne State University School of Medicine.
T. Alp Ikizler is a nephrologist, currently holding the Catherine McLaughlin Hakim chair in Medicine at Vanderbilt University School of Medicine, where he does clinical work and heads a research lab. Born in Istanbul, Turkey, he received his M.D. from the Istanbul University Faculty of Medicine.
Nathan W. Levin is an American physician and founder of the Renal Research Institute, LLC., a research institute dedicated to improving the outcomes of patients with kidney disease, particularly those requiring dialysis. Levin is one of the most prominent and renowned figures in clinical nephrology as well as nephrology research. He has authored multiple book chapters and over 350 peer-reviewed publications, including articles in leading journals such as Nature, the New England Journal of Medicine, and The Lancet.
Aluminium toxicity in people on dialysis is a problem for people on haemodialysis. Aluminium is often found in unfiltered water used to prepare dialysate. The dialysis process does not efficiently remove excess aluminium from the body, so it may build up over time. Aluminium is a potentially toxic metal, and aluminium poisoning may lead to mainly three disorders: aluminium-induced bone disease, microcytic anemia and neurological dysfunction (encephalopathy). Such conditions are more prominently observed in people with chronic kidney failure and especially in people on haemodialysis.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). It is used in form of chewable tablets.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)